Advertisement

Topics

Avacta Group Plc focused on securing third-party deals for both sides of the business

11:54 EDT 14 Jun 2018 | Proactive Investors

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), talks Proactive's Andrew Scott through the latest developments across the business.

Looking ahead, Smith says: ''The priorities for us without doubt are third party deals  on both sides - be they licensing deals, supply deals etc on the reagents and diagnostics side and we've got a really full pipeline of high quality partners evaluating the technology''.

''We have sufficient going on in the pipeline to be confident those deals will start to come through this year and into 2019 and onwards''.

''On the therapeutics side we've got a lot of confidence now we can do deals at a preclinical stage''.

Smith also discusses the appointment of Dr Eliot Forster as non-executive chairman to the board.

Original Article: Avacta Group Plc focused on securing third-party deals for both sides of the business

NEXT ARTICLE

More From BioPortfolio on "Avacta Group Plc focused on securing third-party deals for both sides of the business"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...